BioSpace News Archive

BioSkryb, Inc., a developer of genomic amplification technologies, today reported the release of foundational data before publication on the preprint server, bioRxiv, demonstrating the superior ability of primary template-directed amplification (PTA) to accurately and uniformly amplify the genomes of single cells.

Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, and Hikma Pharmaceuticals, a multi-national pharmaceutical company and leading licensing partner in the Middle East and North Africa (“MENA”)

CHO Plus (www.CHO-Plus.com), an early-stage innovation company developing technology to vastly increase the productivity of cells used to manufacture therapeutic proteins, announced today that it has entered into a research collaboration agreement with Janssen Biotech, Inc. (Janssen), one of the Pharmaceutical Companies of Johnson & Johnson.

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval of the Company’s 3-antigen prophylactic hepatitis B vaccine candidate

Sunshine Biopharma Inc. (OTC PINK:SBFM), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today announced that it has received the third tranche of funding under the recently announced committed minimum financing of $2,000,000 with RB Capital Partners Inc.

Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary and infectious diseases, today announced that the first patient has been enrolled in its REBUILD Phase 3 registrational clinical study evaluating INOpulse®, a pulsed inhaled nitric oxide therapy, as a potential treatment for fibrotic interstitial lung disease (fILD).

MediGO, the Baltimore-based technology company applying disruptive technology solutions to organ transplantation logistics, announced a first-ever partnership with Nevada Donor Network, a leading organ procurement organization that maximizes the gift of life and health through organ, eye and tissue donation.

Regulus Therapeutics Inc., a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, announced that it has entered into a definitive securities purchase agreement in connection with a private placement to existing institutional and other accredited investors as well as new institutional investors.

Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced that it will host a virtual Investor and Analyst Event on Friday, December 11, 2020, at 1:00 p.m. CT / 2:00 p.m. ET

Applied UV Announces U.S. Patent to be Issued for a System to Neutralize Pathogens on Tactile Surfaces, Including Bank ATMs